Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicagrel vs Clopidogrel PK/PD in Healthy Subjects with Different CYP2C19 Phenotypes
NCT05162053Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of vicagrel in acute coronary syndrome (ACS) (5 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Inhibition of Platelet Aggregation at Day 31, Platelet Reactivity Index at Day 31 and 2 more. Started Dec 2021; status: completed.
02
Drugs
vicagrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05162053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162053.